Journal Publications
I have over 280 publications in high-quality peer-reviewed journals.
The most important have been:


  •  Preiss, D., Seshasai, S. R. K., Welsh, P., Murphy, S. A., Ho, J. E., Waters, D. D., Ray, KK (2011, June 22). Risk of Incident Diabetes With Intensive-Dose Compare With Moderate-Dose Statin Therapy A Meta-analysis. JAMA, 2011, 305(24), 2556 2564

  • Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mozenson, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D. for the SAVOR-TIMI 53 Steering Committee and Investigators . Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 2013 Oct 3;369(14):1317-26.

  • Swerdlow D,….. Ray KK……Sattar N. HMG coenzyme A reductase inhibition, Type 2 diabetes and bodyweight: evidence from genetic analyses and randomised trials Lancet 2014 Sep 24<sup>th</sup>, pii: S0140-6736(14)61183-1. doi: 10.1016/S0140-6736(14)61183-1

  • Ray KK, Vallejo-Vaz AJ. <a href="">The evolving role of CETP inhibition: beyond HDL cholesterol.</a> Lancet. 2015 Aug 1;386(9992):412-4. doi: 10.1016/S0140-6736(15)60608-0. Epub 2015 Jun 2. PMID: 26047976.

  • Vallejo-Vaz AJ, Ray KK. <a href="">Cholesterol efflux capacity as a novel biomarker for incident cardiovascular events: has high-density lipoprotein been resuscitated?</a> Circ Res. 2015 May 8;116(10):1646-8. doi: 10.1161/CIRCRESAHA.115.305938. PMID: 25953923.

  • Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, .März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; for the European Atherosclerosis Society Consensus Panel. <a href="">Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.</a> Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18. Review. PMID: 25694464.

  • Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. <a href="">The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.</a> Eur Heart J.

  • Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, Michishita I, Nozue T, Sugiyama S, Tsimikas S, Yoshida H, Ray KK. <a href="">Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.</a> Atherosclerosis. 2015 Aug;241(2):409-18. doi: 10.1016/j.atherosclerosis.2015.06.001. Epub 2015 Jun 4. PMID: 26074315. 

  • Twitter Social Icon
  • Facebook Social Icon
  • LinkedIn Social Icon

© 2017 by Prof Kausik Ray. Proudly created with